1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Cabotegravir + rilpivirine
Trade Name:
Cabenuva
Manufacturer/Distributor:
ViiV Healthcare ULC
Classification:
Antiretroviral agent
ATC Class:
J05AR - antivirals
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/03/18
Date Marketed in Canada (yyyy/mm/dd):
2020/03/19
Presentation:
Injection: 200 mg/mL cabotegravir and 300 mg/mL rilpivirine
Comments:
For use as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
Back to:
Drug Product Listings 
